These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22215904)

  • 1. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.
    Alcalá AM; Flaherty KT
    Clin Cancer Res; 2012 Jan; 18(1):33-9. PubMed ID: 22215904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF in melanoma: current strategies and future directions.
    Salama AK; Flaherty KT
    Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
    Welsh SJ; Rizos H; Scolyer RA; Long GV
    Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting BRAF in melanoma: biological and clinical challenges.
    MandalĂ  M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Halilovic E; Solit DB
    Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging BRAF inhibitors for melanoma.
    Sabbatino F; Wang Y; Wang X; Ferrone S; Ferrone CR
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):431-43. PubMed ID: 24073999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Raf inhibitors.
    McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):633-48. PubMed ID: 19715444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.
    Pritchard AL; Hayward NK
    Clin Cancer Res; 2013 May; 19(9):2301-9. PubMed ID: 23406774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel inhibitors in the treatment of metastatic melanoma.
    Kalinsky K; Haluska FG
    Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer research. Melanoma drug vindicates targeted approach.
    Garber K
    Science; 2009 Dec; 326(5960):1619. PubMed ID: 20019269
    [No Abstract]   [Full Text] [Related]  

  • 14. Protein kinase inhibitors in melanoma.
    Eigentler TK; Meier F; Garbe C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2195-201. PubMed ID: 23992377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
    Sondak VK; Smalley K
    Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
    [No Abstract]   [Full Text] [Related]  

  • 16. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.
    Lai F; Jin L; Gallagher S; Mijatov B; Zhang XD; Hersey P
    Adv Pharmacol; 2012; 65():27-43. PubMed ID: 22959022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
    Chen G; Davies MA
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Narrative review: BRAF opens the door for therapeutic advances in melanoma.
    Flaherty KT
    Ann Intern Med; 2010 Nov; 153(9):587-91. PubMed ID: 21041578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectively targeting BRAF in melanoma: a formidable challenge.
    Fecher LA; Amaravadi R; Schuchter LM
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):410-1. PubMed ID: 18710372
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
    Nickoloff BJ; Vande Woude G
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.